The prevention of the staurosporine-induced apoptosis by Bcl-XL, but not by Bcl-2 or caspase inhibitors, allows the extensive differentiation of human neuroblastoma cells

Simple item page
dc.contributor.authorYuste Mateos, Víctor J. (Víctor José)
dc.contributor.authorSánchez-López, Isabel
dc.contributor.authorSolé Serra, Carme
dc.contributor.authorEncinas Martín, Mario
dc.contributor.authorBayascas Ramírez, José Ramón
dc.contributor.authorBoix Torras, Jacint
dc.contributor.authorComella i Carnicé, Joan Xavier
dc.date.accessioned2016-05-12T08:29:02Z
dc.date.embargoEndDate2025-01-01
dc.date.issued2002
dc.description.abstractStaurosporine is one of the best apoptotic inducers in different cell types including neuroblastomas. In this study we have compared the efficiency and final outcome of three different anti-apoptotic strategies in staurosporine-treated SH-SY5Y human neuroblastoma cells. At staurosporine concentrations up to 500 nm, z-VAD.fmk a broad-spectrum, noncompetitive inhibitor of caspases, reduced apoptosis in SH-SY5Y cells. At higher concentrations, z-VAD.fmk continued to inhibit caspases and the apoptotic phenotype but not cell death which seems to result from oxidative damage. Stable over-expression of Bcl-2 in SH-SY5Y protected cells from death at doses of staurosporine up to 1 microm. At higher doses, cytochrome c release from mitochondria occurred, caspases were activated and cells died by apoptosis. Therefore, we conclude that Bcl-2 increased the threshold for apoptotic cell death commitment. Over-expression of Bcl-X(L) was far more effective than Bcl-2. Bcl-X(L) transfected cells showed a remarkable resistance staurosporine-induced cytochrome c release and associated apoptotic changes and survived for up to 15 days in 1 microm staurosporine. In these conditions, SH-SY5Y displayed a remarkable phenotype of neuronal differentiation as assessed by neurite outgrowth and expression of neurofilament, Tau and MAP-2 neuronal specific proteins.ca_ES
dc.description.sponsorshipThis work was founded by Spanish Govern Comisión Interministerial de Ciencia y Tecnología through the Plan Nacional de Salud y Farmacia (contract numbers SAF2000-0164-C02-01 and 1FD97-0514-02-01) and Ajuntament de Lleida. VJY is a predoctoral fellow supported by the European Union contracts BIO4-CT96-0433 and QLG3-CT-1999-00602. JRB was supported by grant 1FD97-0514- C02-01 from Spanish Ministry of Science and Technology.ca_ES
dc.identifier.doihttps://doi.org/10.1046/j.0022-3042.2001.00695.x
dc.identifier.idgrec004929
dc.identifier.issn0022-3042
dc.identifier.urihttp://hdl.handle.net/10459.1/57017
dc.language.isoengca_ES
dc.publisherWileyca_ES
dc.relationMICYT/PN2000-2003/SAF2000-0164-C02-01
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1046/j.0022-3042.2001.00695.xca_ES
dc.relation.ispartofJournal of Neurochemistry, 2002, vol. 80, núm. 1, p. 126-139ca_ES
dc.rights(c) International Society for Neurochemistry, 2002ca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccessca_ES
dc.subjectBcl-2ca_ES
dc.subjectBcl-XLca_ES
dc.subjectNeuritogenesisca_ES
dc.subjectSH-SY5Y cellsca_ES
dc.titleThe prevention of the staurosporine-induced apoptosis by Bcl-XL, but not by Bcl-2 or caspase inhibitors, allows the extensive differentiation of human neuroblastoma cellsca_ES
dc.typearticleca_ES
dc.type.versionpublishedVersionca_ES
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Articles publicats (Medicina Experimental)